Animal models of the cancer anorexia-cachexia syndrome

被引:74
作者
Bennani-Baiti, Nabila [1 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Taussig Canc Ctr, Sect Palliat Med & Suppport Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Ctr, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44106 USA
关键词
Animal models; Cancer cachexia; Anorexia; Wasting; TUMOR-BEARING RATS; PROTEOLYSIS-INDUCING FACTOR; NECROSIS-FACTOR-ALPHA; LIPID-MOBILIZING FACTOR; GROWTH-FACTOR-I; WEIGHT-LOSS; SKELETAL-MUSCLE; THERAPEUTIC STRATEGIES; PROTEIN-TURNOVER; MESSENGER-RNA;
D O I
10.1007/s00520-010-0972-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aims Cancer cachexia, a complex wasting syndrome, is common in palliative medicine. Animal models expand our understanding of its mechanisms. A review of cancer cachexia and anorexia animal models will help investigators make an informed choice of the study model. Results and discussion Cancer-anorexia cachexia animal models are numerous. No one is ideal. The choice should depend on the research question. To investigate cancer-anorexia cachexia independent of pro-inflammatory cytokine effects, the MAC16 ADK and XK1 are useful. MAC16 ADK helps study the host's tumor metabolic effects, independent of any anorexia or inflammation. XK1 is both anorectic and cachectic, but data about it is limited. All other models induce a host inflammatory response. The Walker 256 ADK and MCG 101 are best avoided due to excessive tumor growth. Since individual models do not address all aspects of the syndrome, use of a combination seems wise. Suggested combinations: MAC16-ADK (non-inflammatory and non-anorectic) with YAH-130 (inflammatory, anorectic, and cachectic), Lewis lung carcinoma (slow onset anorexia) or prostate adenocarcinoma (inflammatory, anorectic but not cachectic) with YAH-130.
引用
收藏
页码:1451 / 1463
页数:13
相关论文
共 75 条
  • [1] The past, present and future of multi-targeted cancer treatment "Naturally": Food for thought Foreword
    Aggarwal, Bharat B.
    [J]. CANCER LETTERS, 2008, 269 (02) : 187 - 188
  • [2] Leptin
    Ahima, RS
    Flier, JS
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 2000, 62 : 413 - 437
  • [3] ACTIVATION OF THE ATP-UBIQUITIN-PROTEASOME PATHWAY IN SKELETAL-MUSCLE OF CACHECTIC RATS BEARING A HEPATOMA
    BARACOS, VE
    DEVIVO, C
    HOYLE, DHR
    GOLDBERG, AL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (05): : E996 - E1006
  • [4] Baracos VE, 2000, NES NUTR WS, V4, P167
  • [5] Baracos VE, 2006, PHARMACOTHERAPY CACH, P101
  • [6] Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1111/j.1553-2712.2003.tb00056.x
  • [7] CHARACTERIZATION OF DIFFERENTIATION FACTOR LEUKEMIA INHIBITORY FACTOR EFFECT ON LIPOPROTEIN-LIPASE ACTIVITY AND MESSENGER-RNA IN 3T3-L1 ADIPOCYTES
    BERG, M
    FRAKER, DL
    ALEXANDER, HR
    [J]. CYTOKINE, 1994, 6 (04) : 425 - 432
  • [8] Increased muscle ubiquitin mRNA levels in gastric cancer patients
    Bossola, M
    Muscaritoli, M
    Costelli, P
    Bellantone, R
    Pacelli, F
    Busquets, S
    Argilès, J
    Lopez-Soriano, FJ
    Civello, IM
    Baccino, FM
    Fanelli, FR
    Doglietto, GB
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 280 (05) : R1518 - R1523
  • [9] Cytokine-hormone interactions:: Tumor necrosis factor α impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts
    Broussard, SR
    McCusker, RH
    Novakofski, JE
    Strle, K
    Shen, WH
    Johnson, RW
    Freund, GG
    Dantzer, R
    Kelley, KW
    [J]. ENDOCRINOLOGY, 2003, 144 (07) : 2988 - 2996
  • [10] Anticachectic effects of formoterol:: A drug for potential treatment of muscle wasting
    Busquets, S
    Figueras, MT
    Fuster, G
    Almendro, V
    Moore-Carrasco, R
    Ametller, E
    Argilés, JM
    López-Soriano, FJ
    [J]. CANCER RESEARCH, 2004, 64 (18) : 6725 - 6731